BLAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ADMELOG (insulin lispro) by Sanofi is analogs, including insulin lispro products. Approved for type 1 diabetes mellitus, type 2 diabetes mellitus, diabetes mellitus. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADMELOG (insulin lispro) is a rapid-acting insulin analog administered via subcutaneous or intravenous injection that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. It is indicated for Type 1 and Type 2 Diabetes Mellitus, gestational diabetes, and hyperglycemia management. The drug represents a biosimilar alternative to innovator insulin lispro products in the competitive insulin market.
$1MPart D
PeakProduct is at peak lifecycle stage with minimal Part D penetration ($1M), indicating limited commercial momentum despite established market presence since 2017.
Mechanism of Action
analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
Pharmacologic Class:
Insulin Analog
Indications (3)
Worked on ADMELOG at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.